Morphine and P2Y12 Inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis.

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Morphine is commonly used for pain management in ST-elevation myocardial infarction (STEMI).
• Morphine administration can reduce P2Y12 platelet inhibition, a critical pathway for antiplatelet therapy efficacy.
• The clinical significance of morphine-induced P2Y12 inhibition modulation in STEMI is not well-established.

Purpose of the Study:

• To evaluate the impact of morphine on platelet inhibition and clinical outcomes in patients with STEMI.
• To conduct a meta-analysis of existing studies to assess the association between opiate use and angiographic and clinical endpoints in STEMI.

Main Methods:

• A systematic literature search identified seven eligible studies for meta-analysis.
• Outcomes assessed included 11 angiographic and clinical metrics.
• A random effects model was employed to analyze data and assess heterogeneity between studies.

Main Results:

• Opiate administration was associated with a statistically significant decrease in achieving postprocedural Thrombolysis in Myocardial Infarction (TIMI) 2 flow compared to placebo (RR 0.71, p=0.03).
• No significant differences were observed between opiate and placebo groups for other key outcomes, including infarct size, microvascular obstruction, mortality, stroke, and left ventricular ejection fraction.
• Specific non-significant findings included infarct size (OR -0.12), microvascular obstruction (SMD 0.02), and postprocedural TIMI 3 flow (OR 1.23).

Conclusions:

• Opiate use in STEMI correlates with worse angiographic outcomes, particularly reduced postprocedural TIMI 2 flow.
• Despite the observed angiographic differences, the meta-analysis suggests that these effects are not clinically consequential for STEMI patients.